Výsledky vyhledávání - "Heinz Lubenau"

Akademický článek

A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer

Autor: Friedrich H. Schmitz-Winnenthal, Nicolas Hohmann, Thomas Schmidt, Lilli Podola, Tobias Friedrich, Heinz Lubenau, Marco Springer, Sébastien Wieckowski, Klaus M. Breiner, Gerd Mikus, Markus W. Büchler, Anne-Valerie Keller, Ruhan Koc, Christoph Springfeld, Phillip Knebel, Mariana Bucur, Lars Grenacher, Walter E. Haefeli, Philipp Beckhove

Publikováno v: OncoImmunology, Vol 7, Iss 4 (2018)

VXM01 is a first-in-kind orally applied tumor vaccine based on live attenuated Salmonella typhi carrying an expression plasmid encoding VEGFR2, an antigen expressed on tumor vasculature and a stable and accessible target for anti-angiogenic intervent

Externí odkaz: https://doaj.org/article/f1654b6e955543cab1a035533acfbe75

Zobrazit plný text záznamu

Abstract 733: Modulating T cell immunity in tumors by targeting PD-L1 and neoantigens using a live attenuated oral Salmonella platform

Autor: Marc R. Mansour, Ming Wei, Heinz Lubenau, Sébastien Wieckowski, Lilli Podola, Philipp Beckhove, Amine Adda Berkane, Philippe Slos, Klaus M. Breiner, Anne-Lucie Nugues, Albrecht Meichle, Heiko Smetak

Publikováno v: Cancer Research. 78:733-733

Significant progresses have been achieved recently in cancer vaccines that aim at engaging or reengaging tumor directed T cells, in particular in the rapidly growing field of personalized immunotherapy. Yet novel immunization solutions to produce eff

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dfa239300613df6a1c2b8f46ac0823e8
https://doi.org/10.1158/1538-7445.am2018-733

Zobrazit plný text záznamu

Abstract B196: Live attenuated oral Salmonella platform for effective targeting of multiple tumor-associated epitopes and PD-L1

Autor: Matthias Schroff, Beckhove Philipp, Klaus M. Breiner, Lilli Podola, Heiko Smetak, Heinz Lubenau, Marc Mansour, Albrecht Meichle, Ming Wei, Sébastien Wieckowski, Anne-Lucie Nugues, Philippe Slos, Marco Springer, Iris Kobl, Amine Adda Berkane

Publikováno v: Molecular Cancer Therapeutics. 17:B196-B196

Significant progress has been achieved recently in cancer vaccines that aim at engaging or reengaging the tumor immunity, in particular in the rapidly growing field of personalized immunotherapy. Yet novel immunization solutions to deliver efficientl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7a22320954cf592efbbb1278a2688b4f
https://doi.org/10.1158/1535-7163.targ-17-b196

Zobrazit plný text záznamu

Oral DNA vaccination targeting VEGFR-2 combined with anti-PD-L1 avelumab in patients with progressive glioblastoma, a phase I/II study: NCT03750071

Autor: Lilli Podola, Wolfgang Wick, Olivier Chinot, Heinz Lubenau, Michael Platten, Frédéric Dhermain, Martin J. van den Bent, Antje Wick, Marc R. Mansour

Publikováno v: Journal of Clinical Oncology. 37:TPS2076-TPS2076

TPS2076 Background: The vaccine (VXM01) is a VEGFR-2 coding DNA vaccine, using a Salmonella Ty21a carrier for oral application. VEGFR-2 is over-expressed in glioblastoma and serves as a promising target for VEGFR-2 primed T cells with the potential t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::113d8d5197eaad168b5db3e2402e2333
https://doi.org/10.1200/jco.2019.37.15_suppl.tps2076

Zobrazit plný text záznamu

Abstract 4558: Immunogenicity and antitumor efficacy of live attenuated Salmonella typhimurium-based oral T-cell vaccines VXM01m, VXM04m and VXM06m

Autor: Lilli Podola, Iris Kobl, Klaus M. Breiner, Heinz Lubenau, Ming Wei, Albrecht Meichle, Caroline Mignard, Zina Koob, Sébastien Wieckowski, Matthias Schroff, Amine Adda Berkane, Marco Springer, Philipp Beckhove

Publikováno v: Cancer Research. 77:4558-4558

Significant progresses have been recently accomplished in immuno-oncology and in the development of cancer immunotherapies. However, novel solutions are necessary to overcome the peripheral tolerance and the immunosuppressive tumor microenvironment t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9fcbcaff352aae291ec93b576cfcbb35
https://doi.org/10.1158/1538-7445.am2017-4558

Zobrazit plný text záznamu

ATIM-35. VXM01 PHASE I STUDY IN PATIENTS WITH PROGRESSIVE GLIOBLASTOMA – FINAL RESULTS

Autor: Andreas von Deimling, Andreas Unterberg, Heinz Lubenau, Antje Wick, Friedrich Hubertus Schmitz Winnenthal, Anne-Valerie Keller, Lilli Podola, Martin Bendszus, Dennis Riehl, Felix Sahm, Philipp Kickingereder, Christine Jungk, Christel Herold-Mende, Michael Platten, Sébastien Wieckowski, Philipp Beckhove, Wolfgang Wick

Publikováno v: Neuro-Oncology. 20:vi9-vi9

BACKGROUND. VXM01 consists of the attenuated Salmonella Typhi Ty21a delivering a plasmid encoding vascular endothelial growth factor receptor 2 (VEGFR2) into the Peyer’s patches via the oral route of administration. The vaccine elicits a systemic T

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95eb405a12bc96da6ba8085a5835f412
https://doi.org/10.1093/neuonc/noy148.030

Zobrazit plný text záznamu

Live attenuated oral Salmonella platform for effective T- and B-cell targeting of PD-L1

Autor: Philippe Slos, Amine Adda Berkane, Marc R. Mansour, Anne-Lucie Nugues, Klaus M. Breiner, Albrecht Meichle, Philipp Beckhove, Ming Wei, Iris Kobl, Lilli Podola, Sébastien Wieckowski, Matthias Schroff, Heinz Lubenau, Heiko Smetak

Publikováno v: Journal of Clinical Oncology. 36:74-74

74 Background: Significant progresses have been recently achieved in cancer vaccines, yet novel immunization solutions to deliver efficiently tumor-associated antigens to professional antigen-presenting cells, and to overcome the peripheral tolerance

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::12b5d0013cda0114fc46236b94502556
https://doi.org/10.1200/jco.2018.36.5_suppl.74

Zobrazit plný text záznamu

XM02, the First Biosimilar G-CSF, is Safe and Effective in Reducing the Duration of Severe Neutropenia and Incidence of Febrile Neutropenia in Patients with Small Cell or Non-small Cell Lung Cancer Receiving Platinum-Based Chemotherapy

Autor: Ulrich Gatzemeier, Heinz Lubenau, Mircea Dediu, Tudor Ciuleanu, Elena Ganea-Motan, Auro Del Giglio

Publikováno v: Journal of Thoracic Oncology. 4:736-740

Background Recombinant granulocyte colony-stimulating factors such as Neupogen are used to treat chemotherapy-induced neutropenia. The aim of the study was to show that a new granulocyte colony-stimulating factor, XM02, is as safe and effective as Ne

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81b9c0c3060adf0ec9e35db5c036645d
https://doi.org/10.1097/jto.0b013e3181a52964

Zobrazit plný text záznamu

XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy

Autor: Laimonas Griskevicius, Heinz Lubenau, Andreas Engert, Y. Zyuzgin, A. del Giglio

Publikováno v: Leukemia & Lymphoma. 50:374-379

Recombinant granulocyte colony-stimulating factors (G-CSFs) such as filgrastim or lenograstim are being used to treat chemotherapy-induced neutropenia. The aim of the present study was to investigate a new G-CSF, XM02, in comparison to filgrastim in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d2f264ee19d2eae8b8eac6c9f1d4711
https://doi.org/10.1080/10428190902756081

Zobrazit plný text záznamu

Plný text ve formátu HTML

Vyhledávací nástroje:

Upřesnit hledání